Indication Selection

Discover and evaluate novel indications for your target of interest by the unique combination of Euretos computational disease models and direct access to the Euretos AI Platform.

 

Accelerate and de-risk indication selection

We work closely with many pharmaceutical & biotech companies to accelerate and de-risk their indication selection process. Take a biomolecular data-driven approach and empower your domain experts to evaluate results and draw their own, evidence based conclusions!

Ranked indication predictions from AI-driven computational disease models
Data-driven approach that minimises potential literature bias
Your domain experts assess results using the Euretos AI Platform
Tailored to your situation by including specific data or algorithms
Euretos
Indication Selection

Data-driven, novel indication candidates

Euretos computational disease models predict novel target-indication combinations by assessing whether a target’s biological interactors are linked to known disease associations. These ranked indication predictions can then be reviewed independently by our client's domain experts using the Euretos AI Platform.

SCIENTISTcomlogo     We support purchasing via scientist.com and science exchange!     Science_Exchange_logo

 

Euretos
Indication Selection

Minimise literature bias in indication discovery

To find truly novel indications, we focus on biomolecular and experimental data. By taking into account the indications associated with a target’s biological interaction networks we find yet unexplored disease associations.
Euretos
Indication Selection

Empower your domain experts to evaluate indication predictions

We provide our client's domain experts access to the Euretos AI Platform to evaluate the predicted indications. Here they can assess key target and disease aspects such as multi-omics interactions, gene expression in tissues, cell types and tumors, pathway interactions, regulatory and signalling responses, gene variants, clinical trials, target tractability and patents.
Enabling world leading pharma, biotech and academic institutions
Genmab
Janssen and Janssen Pharmaceutical Companies
Leiden Academic Centre for Drug Research
Astra Zeneca
Boehringer Ingelheim
Tufts University
Euretos
Indication Selection

Tailored to your situation

On request we accommodate customer specific needs in the project approach such as including additional data (public or proprietary), computational algorithm adjustments or text mining.
Euretos
Indication Selection

A collaborative research approach

Combine your proprietary data and therapeutic expertise with our computational disease models, translational consultants and AI platform to gain collaborative, data-driven disease insights.

Case study

Find out how Euretos helped find novel indications in rare diseases. Submit the below form and get the case study:

Enabling world leading pharma, biotech and academic institutions
janssen-logo
Logo Daiichi Sankyo
Logo EMC-1
Lundbeck_Euretos
Logo Sanofi-1
Logo LUMC-1

Transforming Disease and Drug Research

Get started Free access for academic users!
Request a Demo